XYNOMIC PHARMACEUTICALS HOLDINGS, INC. - FORM S-1 - EX-10.3 - FORM OF LETTER AGREEMENT BETWEEN BISON CAPITAL HOLDING COMPANY LIMITED, OUR SPON - June 1, 2017

Attached files

file filename
EX-10.11 - UNIT SUBSCRIPTION AGREEMENT BETWEEN THE REGISTRANT AND EARLYBIRDCAPITAL - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex10xi_bisoncap.htm
EX-10.1 - FORM OF LETTER AGREEMENT AMONG THE REGISTRANT, EARLYBIRDCAPITAL, INC. AND EACH O - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex10i_bisoncap.htm
EX-23.1 - CONSENT OF MARCUM LLP - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex23i_bisoncap.htm
EX-10.8 - FORM OF REGISTRATION RIGHTS AGREEMENT BETWEEN THE REGISTRANT AND SECURITY HOLDER - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex10viii_bisoncap.htm
EX-10.7 - AMENDED AND RESTATED UNIT SUBSCRIPTION AGREEMENT BETWEEN THE REGISTRANT, EARLYBI - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex10vii_bisoncap.htm
EX-10.4 - FORM OF ESCROW AGREEMENT BETWEEN THE REGISTRANT, CONTINENTAL STOCK TRANSFER & TR - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex10iv_bisoncap.htm
EX-10.2 - FORM OF INVESTMENT MANAGEMENT TRUST AGREEMENT BETWEEN CONTINENTAL STOCK TRANSFER - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex10ii_bisoncap.htm
EX-8.1 - FORM OF TAX OPINION OF HUNTER TAUBMAN FISCHER &LI LLC - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex8i_bisoncap.htm
EX-5.2 - FORM OF OPINION OF HUNTER TAUBMAN FISCHER &LI LLC - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex5ii_bisoncap.htm
EX-4.7 - FORM OF RIGHT AGREEMENT BETWEEN CONTINENTAL STOCK TRANSFER & TRUST COMPANY AND T - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex4vii_bisoncapital.htm
EX-4.6 - FORM OF UNIT PURCHASE OPTION BETWEEN THE REGISTRANT AND EARLYBIRDCAPITAL, INC. - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex4vi_bisoncapital.htm
EX-4.5 - FORM OF WARRANT AGREEMENT BETWEEN CONTINENTAL STOCK TRANSFER & TRUST COMPANY AND - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex4v_bisoncapital.htm
EX-4.4 - SPECIMEN RIGHT CERTIFICATE - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex4iv_bisoncapital.htm
EX-4.3 - SPECIMEN WARRANT CERTIFICATE - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex4iii_bisoncapital.htm
EX-4.1 - SPECIMEN UNIT CERTIFICATE - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex4i_bisoncapital.htm
EX-1.2 - LETTER AGREEMENT BETWEEN THE REGISTRANT AND EARLYBIRDCAPITAL - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex1ii_bisoncapital.htm
EX-1.1 - FORM OF UNDERWRITING AGREEMENT - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017ex1i_bisoncapital.htm
S-1 - REGISTRATION STATEMENT - XYNOMIC PHARMACEUTICALS HOLDINGS, INC.fs12017_bisoncapital.htm

Exhibit 10.3

 

Bison Capital Acquisition Corp.

609-610 21st Century Tower

No. 40 Liangmaqiao Road

Chaoyang District, Beijing, China

 

__________, 2017

 

Bison Capital Holding Company Limited

609-610 21st Century Tower

No. 40 Liangmaqiao Road

Chaoyang District, Beijing, China

 

Ladies and Gentlemen:

 

This letter will confirm our agreement that, commencing on the effective date (the “Effective Date”) of the registration statement (the “Registration Statement”) for the initial public offering (the “IPO”) of the securities of Bison Capital Acquisition Corp. (the “Company”) and continuing until the earlier of (i) the consummation by the Company of an initial business combination or (ii) the Company’s liquidation (in each case as described in the Registration Statement) (such earlier date hereinafter referred to as the “Termination Date”), Bison Capital Holding Company Limited, a company incorporated in the Cayman Islands (“Bison Capital”), shall make available to the Company certain office space and administrative and support services as may be required by the Company from time to time, situated at 609-610 21st Century Tower, No. 40 Liangmaqiao Road, Chaoyang District, Beijing, China (or any successor location). In exchange therefore, the Company shall pay Bison Capital the sum of $5,000 per month on the Effective Date and continuing monthly thereafter until the Termination Date. Bison Capital hereby agrees that, solely with respect to this letter agreement, it does not have any right, title, interest or claim of any kind in or to any monies that may be set aside in a trust account (the “Trust Account”) that may be established upon the consummation of the IPO (“Claim”) and hereby waives any Claim it may have in the future as a result of, or arising out of, this letter agreement and will not seek recourse against the Trust Account for any reason whatsoever relating to this letter agreement. No party hereto may assign either this letter agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other party, provided that Bison Capital may assign this letter agreement to an affiliate without the prior written approval of the Company. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee.

 

  Very truly yours,
   
  BISON CAPITAL ACQUISITION CORP.
   
  By:  
  Name: James Jiayuan Tong
 

Title:

 Chief Executive Officer and
Chief Financial Officer

 

AGREED TO AND ACCEPTED BY:

 

BISON CAPITAL HOLDING COMPANY LIMITED

  
     
By:    
Name: Peixin Xu  
Title: Director  

 

XYNOMIC PHARMACEUTICALS HOLDINGS, INC. Reports